Section 1
Executive Summary
The Research Triangle (Raleigh–Durham–Chapel Hill, RTP, plus the Clayton/Holly Springs/Morrisville/Cary ring) is in the middle of a historic biomanufacturing build-out. In 2024–2026 the region booked billions in new capital, and crucially for Brooks, a large share of that spend is greenfield or fit-out construction happening right now — meaning process-instrumentation specs are open and being decided in the exact window of this visit.
Where Brooks fits best, and where to spend time:
- The sweet spot is the cell & gene therapy (CGT) / viral-vector / biologics CDMO cluster. Real bioreactors (gas sparging/blending = thermal MFCs), large WFI/buffer/media/CIP utility loops (clamp-on ultrasonic, ideal because non-invasive on validated single-use lines), and precise downstream/fill-finish dosing (low-flow Coriolis). The strongest smaller/mid targets — OXB, Advanced Medicine Partners, Kriya, Kincell Bio, Alcami, KBI — all have active 2026 build-outs or new arrivals, the single best buying trigger.
- A second tier is process-development / formulation / specialty-manufacturing scale-ups (Lindy Biosciences, ChromaGenix, Synoligo, Cellectis, iOrganBio) where the fit is real but smaller and skews liquid (Coriolis) plus inert-gas (thermal).
- Many regional "biotechs" are virtual/computational/clinical-development or analytical-testing shops (Slate, Ten63, FlashPath, Solvias, Pace) with no point of consumption for flow hardware. Skip for product selling — though a few founders are excellent network nodes.
- The big multinationals already on your covered list (AbbVie, Genentech/Roche, Grifols, AskBio/Bayer) are mostly low priority, but several are notable new greenfield builds; the actionable angle is the EPC firms, skid builders, and fill-line integrators designing those plants, not corporate procurement.
- Universities are both customers and lead engines — NC State BTEC & AIM-Bio, UNC Gene Therapy Center/Vector Core, Duke (Asokan/Gersbach, Duke R&D @RTP), and the community-college BioWork network buy/spec equipment and feed the pipeline.
- Networking is unusually concentrated — almost everything routes through NCBiotech in RTP, and your window lines up with several high-value events (WIB-RTP Career Fair Jun 25, NCLifeSci Lab Space Luncheon Jul 23, Triangle Biotech Tuesday in July). BioLabs NC and First Flight are the densest single rooms for meeting startups.
Bottom line: Lead with the CGT/viral-vector/biologics CDMOs that are building or fitting out in 2026. Use universities and incubators to surface the next wave of smaller accounts and get warm intros. Treat the multinationals as ecosystem context and integrator/spec-in plays only.
Section 2
Top Company Prospects
High fit Lead with these — smaller / newer scale-up CDMOs with active build-outs
OXB (formerly Oxford Biomedica) ★ TOP PICK — timing
1733 TW Alexander Dr, Durham
- What
- Pure-play cell & gene therapy CDMO; lentiviral (LentiVector/TetraVecta) and AAV viral-vector GMP manufacture.
- Stage
- Established global CDMO (LSE: OXB) but a brand-new US site — acquired a former National Resilience FDA-approved facility (Oct 2025), key functions targeted operational Q1 2026, actively hiring/equipping now. Two operational GMP drug-substance suites + fill-finish suite + a third expansion-ready suite still to be fitted out.
- Brooks fit
- All three. Thermal MFCs for bioreactor gas/sparging in viral-vector culture; clamp-on for WFI/buffer/media/CIP (non-invasive = no breaking validated piping in an inherited facility); Coriolis for chromatography buffer + fill-finish dosing.
- Angle
- Congratulate on the US launch; offer to be the flow-instrumentation standard as they requalify running suites and fit out the third. Lead bioreactor gas control, layer clamp-on for retrofit monitoring, Coriolis for fill-finish. Target site engineering/MSAT + procurement now.
Advanced Medicine Partners (AMP) ★ TOP PICK — greenfield
Durham & Cary
- What
- Standalone AAV gene-therapy CDMO; process dev, AAV manufacturing, analytical. Carved out of Jaguar Gene Therapy's CMC org (Jan 2024). 400+ non-GMP batches on a proprietary high-yield AAV platform.
- Stage
- ~33,000 sq ft across Cary & Durham today; building a 174,000 sq ft GMP facility in Durham right now (~$125M, ~200 jobs 2024–2028). VC-backed (Deerfield, ARCH, Nolan). CEO Andrew Knudten (ex-Jaguar COO).
- Brooks fit
- All three. HEK293-type transfection bioreactors (thermal MFCs); WFI/buffer/media + TFF/chromatography (clamp-on); Coriolis for buffer delivery + fill/finish.
- Angle
- Facility under construction = specs being purchased in this window. Reach CEO Knudten / VP Manufacturing / Facilities lead. Single-source gas + liquid; frame as standardizing flow instrumentation across new suites. (Don't chase the Jaguar entity — it outsources to CDMOs; the process opportunity is AMP.)
Kriya Therapeutics
RTP, Durham
- What
- Next-gen AAV gene therapy (ophthalmology, metabolic, neurology). SIRVE + STRIPE platforms; lead asset KRIYA-825. 51,350 sq ft fully integrated cGMP facility (RTP is the manufacturing site).
- Stage
- Clinical-stage; $320M Series D Sept 2025, >$900M raised; new CMO (Dec 2025) + CFO (Jan 2026). Co-founded/led by RTP veteran Roger Jeffs.
- Brooks fit
- All three. Suspension culture across 1L → 50L/500L/3,000L (thermal MFCs for sparge + overlay — their "same unit ops from research to commercial" = a standardize-on-one-MFC-family pitch); ÄKTA chromatography + vial fill/finish (Coriolis); clamp-on for WFI/buffer/media/CIP.
- Angle
- Congratulate on Series D + build-out; ask whether gas-blending and buffer delivery are standardized across the trains. Roger Jeffs is local — relationship-based approach lands well.
Kincell Bio
20 TW Alexander Dr, Ste 130, RTP
- What
- Cell-therapy CDMO (CAR-T, TCR, Treg, CAR-NK, iPSC) — CMC roadmap through commercial GMP. RTP = their "center of excellence."
- Stage
- Emerging/fast-growing. ~32,800 sq ft, ISO 7 suites expanding from four to six, fully operational by end of Q3 2026; April 2026 expansion; recent client wins (Imugene, RegCell).
- Brooks fit
- Thermal MFCs (gas blending/sparging — accuracy tied to cell viability); Coriolis (media/buffer dosing, fill/finish); clamp-on (WFI/buffer/CIP cleanroom retrofit).
- Angle
- Congratulate on the April 2026 expansion; offer a flow-control assessment for the two new ISO 7 suites before equipment is locked. Target process dev, facilities/engineering, manufacturing ops.
Alcami Corporation
RTP + 4620 Creekstone Dr, Durham
- What
- Mid-size US CDMO (45+ yrs); sterile fill-finish, lyophilization, complex/sterile formulation, high-potency/DEA, analytical. Supports biologics, peptides, oligos, ADCs, CGT.
- Stage
- PE-backed, multi-site. Third sterile fill line online (5 total); 20,000 sq ft analytical lab expansion (finishing 2026); $6.7M Creekstone acquisition (Jan 2026).
- Brooks fit
- Lead liquid (growth is fill-finish/lyo/formulation). Clamp-on for non-invasive WFI/buffer/CIP/SIP on isolator lines; Coriolis for isolator fill-volume + formulation dosing (giveaway matters on high-value product); thermal MFCs for N2 blanketing + lyophilizer backfill.
- Angle
- Time outreach to the 2026 commissioning/qualification window. Target facilities/engineering + validation at RTP.
KBI Biopharma coordinate internally first
3 Durham sites
- What
- Established biologics "Gene-to-GMP" CDMO (JSR Life Sciences). Venture Center (process/analytical/cell-line dev), Hamlin Rd (clinical + commercial cGMP), Patriot Park (commercial plant).
- Stage
- Large, well-established. Patriot Park = $150M, ~150,000 sq ft, 6× 2,000L single-use bioreactors, 200+ staff growing toward 350.
- Brooks fit
- All three, strongly. Thermal MFCs for sparge-gas across six 2,000L SU trains; clamp-on for WFI/buffer/media + CIP; Coriolis for chromatography buffer + formulation/fill dosing.
- Angle
- Pitch clamp-on as a fast, low-validation add for WFI/buffer/CIP, plus MFCs for sparge accuracy at scale. May be a national/strategic account — coordinate internally before pursuing. Best anchor for mapping the RTP supplier ecosystem.
Also high-priority unverified leads in this lane (qualify on the ground): StrideBio (structure-inspired AAV), Locus Biosciences (CRISPR-Cas3 phage), GeneVentiv (AAV hemophilia, UNC spinout), Tune Therapeutics (epigenome editing, >$175M Series B, Durham), Sable Fermentation (new pilot-scale fermentation-for-others — strong fermentation fit).
Medium fit Real flow needs, smaller scale or liquid-skewed
Cellectis (IMPACT facility)
2500 Sumner Blvd, N. Raleigh
- What
- Gene-editing biotech (TALEN); allogeneic UCART CAR-T. IMPACT = 82,000 sq ft GMP plant (opened 2021). Clinical-stage, public, AstraZeneca-backed; 2026 = catalyst/expansion year.
- Brooks fit
- Thermal MFCs (CO2/O2/N2/air sparging — a cell-culture CQA driver); Coriolis (small high-value batches, buffer/media dosing, fill/finish); clamp-on (sterile WFI/buffer/CIP). Medium — CAR-T is single-use intensive, smaller footprint than a mAb plant.
- Angle
- Open on gas-blending repeatability for cell-culture CQAs; position as standardization partner as they scale + expand Raleigh. Target facilities/engineering + MSAT.
iOrganBio
BioLabs Chapel Hill, Franklin St
- What
- Seed-stage (2024; stealth exit Nov 2025, $2M) AI cell-manufacturing platform "CellForge" — closed-loop control of 3D culture environments during hPSC differentiation. Very small (<~10). Founders Delubac (CEO), Chen, Shen.
- Brooks fit
- Thermal MFCs (dynamic software-controllable CO2/O2/N2/air blending — far better than incubator presets, digital I/O integrates into their AI loop); Coriolis (reproducible media/reagent micro-dosing).
- Angle
- Their differentiator is closed-loop gas + liquid control — position Brooks digital devices as the physical actuators behind their "real-time, reproducible, scalable" claims. Caveat: at seed/incubator scale they may be bench/microfluidic — qualify whether they build their own culture hardware. Contact CEO Delubac.
Lindy Biosciences
627 Davis Dr, Ste 400, Morrisville
- What
- Duke spinout; Microglassification protein-formulation tech (dry protein microbeads → low-volume SC self-administration of biologics). ~14–20 staff; ~$27M raised; $20M+ Novartis license (2024) + Lifecore scale-up.
- Brooks fit
- Lead low-flow Coriolis (precise low-volume protein/solvent/buffer metering); thermal MFCs (N2 for microdroplet drying + solvent inerting). De-emphasize clamp-on.
- Angle
- Congratulate on Novartis license + scale-up; ask how they meter low-volume protein/solvent flows moving lab → GMP. Contact process-dev/engineering hires (info@lindybio.com / 919-765-8700).
ChromaGenix (formerly LigaTrap)
1791 Varsity Dr, Ste 150, Raleigh
- What
- Downstream purification supplier — synthetic/peptide affinity ligands & chromatography resins for AAV/viral vector/mRNA/exosome/LNP. NC State roots; formed Apr 2025. Building a 6,500 sq ft GMP+R&D facility ($35M/5-yr, up to 40 jobs).
- Brooks fit
- Coriolis (dosing in ligand conjugation chemistry + buffer/eluent — drives resin lot-to-lot consistency); clamp-on (WFI/PW/buffer/CIP). Gas is a weak fit — keep the pitch on liquid.
- Angle
- Open on the new Raleigh GMP/R&D build (verify construction timeline). Tie dosing accuracy to their resin consistency/QC story. Contacts: Dr. Patrick Gilbert (COO), Prof. Stefano Menegatti (CSO), Chris Major (CEO).
Synoligo Biotechnologies
Morrisville
- What
- CRDO for custom complex modified oligonucleotides (ASO/siRNA/saRNA/miRNA/aptamers/gRNA). Founded 2022; added a 2nd high-throughput facility Oct 2024; scaling toward therapeutic-grade.
- Brooks fit
- Coriolis (mass-based dosing of expensive amidites/activator/oxidizer — reduces costly waste; chromatography buffer); thermal MFCs (Ar/N2 line pressurization + blanketing of moisture-sensitive amidites); clamp-on (solvent + CIP).
- Angle
- "As you scale toward larger therapeutic batches, how are you metering reagent/solvent delivery and inert-gas blanketing?" Lead Coriolis (amidite cost = compelling). CEO Xibo Li, CTO Baozhong Zhao (info@synoligo.com / 919-650-1014). Confirm GMP status = strongest trigger.
Asymchem (Morrisville site)
600 Airport Blvd, Ste 1000
- What
- Global CDMO (1995, NC roots, ~9,000 worldwide). Morrisville = GMP peptide-API & complex-molecule process dev/mfg; large-scale SPPS (>10,000L resin), PDCs, HPAPI.
- Brooks fit
- Liquid-first — Coriolis (mass-based reagent/buffer dosing, chromatography mobile-phase); clamp-on (WFI/process-water/solvent feeds/CIP); thermal MFCs (N2 inerting). No classic bioreactor sparging here.
- Angle
- Open on solid-phase synthesis + downstream chromatography metering and WFI/CIP. Recent automated SPPS lines = active capacity investment. Medium, chemistry-driven.
Sterling Pharma Solutions (Cary site)
1001 Sheldon Dr #101, Cary
- What
- Small-molecule API CDMO (UK HQ); Cary = US base (ex-CiVentiChem). Synthesis, route dev, GMP synthesis, peptides, 14C radiolabelling, controlled substances; mL up to 200L. ~55 staff; recent early-phase expansion.
- Brooks fit
- Thermal MFCs (N2 inerting; H2 flow control for catalytic hydrogenation — confirm H2 on-site, safety-rated); Coriolis (precise reagent/solvent dosing mL–200L, chromatography). Clamp-on lower fit.
- Angle
- "How are you metering inert-gas blanketing and small-volume reagent additions on GMP synthesis/purification trains?" Tie to the recent expansion. Modest opportunity size.
Adverum Biotechnologies (now Eli Lilly)
RTP, Durham County
- What
- Ocular AAV gene therapy (Ixo-vec). Operational 174,000 sq ft GMP AAV plant: four 1,000-L bioreactors + downstream + viral-vector fill/finish. Acquired by Eli Lilly, closed Dec 2025.
- Brooks fit
- All three technically strong — thermal MFCs across the 1,000L train, clamp-on for WFI/buffer/media/CIP, Coriolis for TFF/chromatography + fill/finish.
- Angle
- Operational site running exactly your unit ops. Caveat: Lilly isn't on your covered list (legit target) — but verify whether the site kept purchasing autonomy vs. routing through Lilly corporate. Approach RTP facility/engineering + procurement directly.
CARsgen Therapeutics (NA) verify before pursuing
Durham / RTP
- What
- US arm of Shanghai CAR-T developer; Durham cGMP CAR-T site (opened Feb 2022, ~37,000 sq ft + planned 100,000 sq ft commercial).
- Brooks fit (paper)
- All three — cell-expansion gas control, WFI/buffer/CIP, low-volume autologous fill/finish.
- Status
- Strong distress signals: mfg paused Dec 2023, FDA Warning Letter Jul 2024, clinical holds (lifted Nov 2024), NC incentive grant terminated Feb 2026, "site shut down" reviews, parent refocusing on Shanghai. Quietly confirm the Durham site is live before any effort. An FDA-remediation restart would be a strong re-spec moment; otherwise treat as cold.
Low priority / skip for product selling — note as network or context only
| Org | Why low / skip | Salvage value |
|---|---|---|
| Slate Medicines (Raleigh) | Virtual clinical-dev startup, outsources all mfg — no point of consumption | Lead pointer: chase whichever CDMO makes SLTE-1009 |
| Ten63 Therapeutics (Durham) | AI/computational discovery; only bench-scale wet lab | Low-effort touch; congratulate on $45M close |
| FlashPath AI (Durham) | Pure software/tox-data; zero physical process | Network only — founder Sara Selitsky is well-connected; referral path |
| VQ Biomedical (Cary) | Medtech catheter, not bioprocess | Revisit only if in-house mfg in 2027+ |
| InSoma Bio (Durham) | ELP recombinant protein = real fermentation fit, but pre-commercial, likely outsourced | Early-positioning relationship before GMP scale-up |
| Certera Bio / Persistence Tx / Intra Tx | Pre-seed academic spinouts; bench chemistry/in-vivo, no process | Long-term watch via NC State/UNC commercialization |
| Helixomer (Raleigh) | Preclinical RNA-origami, <10 ppl, plans external IVT/mRNA CDMOs | Watch + referral to their mRNA CDMO |
| Opus Genetics (Durham) | Sponsor; outsources AAV to Resilience (RTP) | Better target = Resilience RTP site |
| Cereius / Solve Tx (Durham BioLabs) | Bench radiochemistry in shared incubator | Revisit if Solve scales radiolabel mfg |
| Coriolis Pharma US (RTP) | Analytical + formulation CRO, new arrival (Mar 2026) | Relationship touch; narrow fill-characterization fit |
| Pace Life Sciences (Morrisville) | Analytical-testing only; process capacity is NH/MN | Skip locally; route process talk to NH/MN reps |
| Solvias (Morrisville) | Analytical/QC testing lab, not process | Network node — tests product for regional CGT/CDMOs |
| Cambrex (Durham) | Analytical/chemistry/storage hub; large multinational | Opportunistic kilo-lab N2/Coriolis only |
| Adroit Pharma Dev (Durham) | Tiny formulation consultancy, no equipment | Skip |
| Abzena (Raleigh) | HQ admin only; process sites out-of-region | Skip locally; refer to CA/PA reps |
| Jaguar Gene Therapy (Cary) | Now a developer; mfg carved out to AMP | Intro path → AMP |
| AskBio (RTP) | Bayer subsidiary (covered tier) | Cluster anchor — track alumni/spinouts |
| AbbVie / Genentech-Roche / Grifols | Large multinationals (covered/skip tier) | See spec-in plays below |
New-build spec-in plays (multinationals — work the integrators, not corporate procurement):
- AbbVie Durham ($1.4B SVP fill-finish campus, 2026–2028) — spec window is NOW. Liquid-first; get on the qualified-vendor list via the EPC + new manufacturing-engineering hires.
- Genentech/Roche Holly Springs (~$2B fill-finish, ops ~2029) — pursue the named EPC + skid/fill-line integrators, not Roche procurement.
- Grifols Clayton (plasma fractionation/fill-finish; $351M+ expansion) — clamp-on is a strong non-invasive door-opener on existing piping during revalidation. Low priority but useful large-account context.
Section 3
Universities & Research Institutes
These are dual-value: they buy/spec bioprocess equipment for pilot plants & core labs, and they originate the smallest spinouts.
NC State — Golden LEAF BTEC, Raleigh highest academic priority
82,500 sq ft with simulated cGMP pilot plant, microbial fermentation + mammalian cell-culture suites, recovery/purification. Fermentation Engineering short courses, contract bioprocess/analytical services; Tier-1 NIIMBL partner, BioMADE founder. They spec/replace flow equipment for teaching + contract work — gas sparging (thermal MFCs) and WFI/buffer/CIP (clamp-on) map directly. Facility tour bookable Jun 19.NC State — AIM-Bio
$27M Novo Nordisk Foundation program (NC State + DTU), ~9 projects on next-gen biomanufacturing, automation/process control, analytical methods. Active equipment/consumable buyer; process-control focus is squarely Brooks-relevant. Lesser-known than BTEC.NC State — Food/Bioprocessing & Nutrition Sciences / Wolfpack Brewing Lab
Production-scale fermentation teaching/research (Dr. John Sheppard) — fermentation gas + media flow needs outside the pharma niche.UNC Gene Therapy Center & Vector Core, Chapel Hill
Founded 1993; full-service AAV/lentiviral vector production for academic/biotech/government clients. High-value bioprocess/purification buyer + source of spinouts (StrideBio, GeneVentiv). Angle: bioreactor gas control + downstream buffer/WFI.Duke — Gene Therapy (Asokan lab) & Gersbach lab
Leading AAV / epigenome-editing groups; origin of Tune, StrideBio science. Strong academic partner/customer + spinout pipeline.Duke Research & Discovery @RTP
Newer RTP campus: 60+ labs, 14+ PIs, BSL-3, flow cytometers, robotics — recent arrival in your exact geography, emerging lab-supply account.UNC Eshelman School of Pharmacy — Pharmacoengineering (DPMP)
Drug delivery/formulation; bioprocessing/formulation instrumentation relevance.UNC Institute for Convergent Science — Gene Therapy Biomanufacturing Foundry
Cross-institutional, scale-up-oriented; emerging infrastructure play — strong fit for the "newer/lesser-known" priority. Engage early.NCCU — BRITE, Durham
~40+ scientists, drug discovery + biomanufacturing; HBCU institute often under-covered by reps focused on Duke/UNC/NC State — differentiated relationship opportunity.Community-college BioWork network
Training-lab equipment buyers + talent contacts (NCBioImpact / BioNetwork): Wake Tech Biotechnologies, Durham Tech (Biogen RTP CoLab), Central Carolina CC (Pittsboro/Chatham), Johnston CC (Clayton; Novo + Grifols advisory board), Vance-Granville CC (Franklinton; statewide BioWork trainer training).How to use them: BTEC + AIM-Bio + UNC Vector Core are the direct equipment/spec targets. Duke MEDx, UNC Innovate Carolina/Launch Chapel Hill, and NC State Research Commercialization (Triangle Venture Day) are the lead engines for the next wave of spinouts.
Section 4
Upcoming Events (June–August 2026)
All dates from the research data; verify rotating dates/venues ~2 weeks out, especially Triangle Biotech Tuesday.
| Date | Event | Venue | Notes / Register |
|---|---|---|---|
| Tue Jun 16, 6:00 PM | NC Bio Pharma Networking Group (June) | Tobacco Wood Brewing, Durham | Free happy-hour mixer. Eventbrite (NCBPNG) |
| Thu Jun 18, 12:30 PM | NCBiotech Career Dev — Career Pivots Panel | NCBiotech, 15 TW Alexander Dr | Midday networking, broad life-sci |
| Thu Jun 18 (weekly), 4:30–6:30 | Frontier RTP "Out of Office" happy hour | Frontier/Hub RTP, 800 Park Offices Dr | Heavy RTP-company attendance |
| Fri Jun 19, 1:30 PM | BTEC facility tour ★ | Golden LEAF BTEC, NC State, Raleigh | Meet educators; see the pilot plant |
| Thu Jun 25, 4:00–7:00 | WIB-RTP 3rd Annual Career Fair ★ | NCBiotech, Durham | Hiring managers + recruiters in one room. community.womeninbio.org |
| Jun 22–25 | BIO International Convention 2026 | (national, off-site) | Many Triangle startups attend; align travel only if convenient |
| Thu Jul 9, 5:30 PM | Raleigh ISSA Chapter Meeting | NCBiotech RTP | IT/security crowd — only if targeting those buyers |
| Tue Jul 14 (expected) | Triangle Biotech Tuesday ★ | Rotating RTP venue | Best grassroots social; 2nd Tue, 5:30–7:30. Confirm on TBT site/LinkedIn |
| Wed Jul 15 | STAEDEAN Lunch & Learn — FDA Form 483 readiness | NCBiotech | Draws QA/manufacturing from local biologics firms |
| Fri Jul 17 | NC Community College Biotech Conf (1st annual) | Eastern NC (~1.5 hr) | Workforce/educator + industry |
| Thu Jul 23, 11:30–2:00 | NCLifeSci Lab Space Luncheon & Forum ★ | Triangle region | Companies expanding space = procurement signals. nclifesci.org |
| Thu Jul 30, 5:30–8:30 | WIB-RTP & AMWA — "Future of the Drug Market" | NCBiotech, Durham | Clinical/regulatory + commercial crowd |
| Tue Aug 11 (expected) | Triangle Biotech Tuesday | Rotating RTP venue | (One source references Aug 28 at Charles River, Durham — verify) |
| Thu Aug 13, 5:30–8:30 | WIB-RTP Summer Bash | Lakewood Social, Durham | Relaxed summer mixer |
| Thu Aug 20, 5:00–7:15 | RTP180 (RTI speaker series + networking) | Frontier 800, Durham | Quarterly lightning talks. frontier.rtp.org |
Watch for newly posted dates: LaunchBio "Larger Than Life Science" (1st-Thu evenings, The Chesterfield, Durham), Triangle Biotech Networking Meeting (likely July), Pace RTP Networking Happy Hour, and any NCBiotech "Life Sciences Outlook: Wake County & the Triangle 2026". The NCBiotech events calendar (ncbiotech.org/events) is the master source — browse manually.
Section 5
Recurring Networking & Where to Be Seen
Anchor venue: NC Biotechnology Center (NCBiotech), 15 TW Alexander Dr, RTP — near RDU, hosts most events, maintains the regional company directory, runs the Emerging Company Development program. Your single best base + source for warm intros.
Densest rooms for meeting many startups at once (make these physical stops)
- BioLabs North Carolina — Durham (42,000 sq ft) + Chapel Hill (~23,000 sq ft, opened 2025). 130+ startups; tenants include iOrganBio. Member socials/seminars/fireside chats. One visit surfaces many seed/Series A tenants. biolabs.io/nc
- First Flight Venture Center (FFVC), RTP. 25,000+ sq ft, up to 40 early-stage life-sci companies; "Test Flight" pitch practice, open houses, socials; BARDA-linked "Wheels UP" cohort. Affordable "First Flight Friends" non-resident membership. ffvcnc.org
- Frontier RTP / Hub RTP. Free coworking + recurring events (RTP180, OOO happy hours, Magnet Triangle Networking).
Recurring associations & meetups to plug into
- Triangle Biotech Tuesday (TBT) — monthly (2nd Tue, Feb–Nov), the most consistent grassroots biotech social. trianglebiotech.com
- NC Bio Pharma Networking Group (NCBPNG) — free monthly happy hour (small-molecule lean). ncbpng.org
- ISPE-CaSA (Carolina-South Atlantic) — most engineering-buyer-relevant. Therapeutic Thursdays, the RTP Golf Tournament, "Swing for a Cause," and the Life Sciences Tech Show (annual, Raleigh Convention Center, ~Feb/Mar — the major regional exhibit/sponsor opportunity for Brooks). ispe-casa.org
- PDA Southeast Chapter — Dinner & Dialogues, facility tours, conferences, Vendor Showcases. pda.org
- CED (Council for Entrepreneurial Development) — Life Science Conference (~1,000 attendees), Venture Connect, Mentor Matching. cednc.org
- WIB-RTP & HBA-RTP — panels, career fair, joint networking.
- LabOps Unite NC — quarterly happy hours for lab ops/facilities/IT/EHS (operational buyers).
- AIChE Eastern NC — chemical/bioprocess engineers; dinner meetings + tours. (National Annual Meeting at DoubleTree RDU/RTP, Dec 1–3, 2026.)
- RTP AgBio + AgTech Meetup / RTAC — for the strong regional ag-bio/fermentation cluster.
Key "connector" contacts for warm intros (relationship capital, not customers)
- NCBiotech — Emerging Company Development program; tracks nearly all NC startups.
- Hatteras Venture Partners — region's leading life-sci VC (>$200M raised 2025; 100+ portfolio).
- Cape Fear BioCapital — seed therapeutics fund (backed Ten63, iOrganBio); planning $100M Fund II.
- Research Triangle Regional Partnership / RTP.org — Gene & Cell Therapy cluster page; co-runs Triangle Venture Day; tracks new arrivals/expansions.
Watch-list of emerging companies to qualify on the ground
(from unverified leads — promising but verify status/footprint before pitching)
- CGT/biologics (likely high fit): StrideBio, Locus Biosciences, GeneVentiv, Tune Therapeutics, Precision BioSciences, Life Edit, Humacyte.
- mRNA / antibody / specialty: GreenLight Biosciences (verify post-restructuring), Genencine, Inhalon Biopharma, Aer Therapeutics, Isolere Bio/Donaldson, Liquidia (new 70,000 sq ft Morrisville cleanroom), Heron Therapeutics (HQ to Cary 2025), United Therapeutics (RTP), Pathalys Pharma.
- Industrial/precision fermentation (strong thermal-MFC fit, often under-covered): Sable Fermentation (high priority), Curie Co, Hoofprint Biome ($15M Series A 2025), Growth Curve Bio, De Novo Foodlabs, Jellatech, BIOMILQ, Ingenza, Novonesis BioAg.
Section 6
Suggested Call Plan
Base out of RTP / near RDU (central, near NCBiotech). Suggested 3–4 working days plus event evenings.
Day 1 — RTP / Durham core your best day
The TW Alexander Drive corridor is dense: OXB (1733) and Kincell Bio (20) are essentially neighbors; Kriya, AMP's Durham build site, and Alcami are all close. Add KBI if internal coordination clears. Anchor the day at NCBiotech (15 TW Alexander) for intros.
Priority order: OXB → AMP → Kriya → Kincell → Alcami.
Evening: TBT (if 2nd-Tue lands), OOO happy hour at Frontier, or an NCBiotech event.
Day 2 — Morrisville / Cary / Raleigh ring medium-fit liquid & specialty
Morrisville: Lindy Biosciences (627 Davis Dr), Synoligo, Asymchem (600 Airport Blvd). Cary: Sterling Pharma (1001 Sheldon Dr) + AMP's Cary lab. Raleigh: Cellectis IMPACT (2500 Sumner Blvd) and ChromaGenix (1791 Varsity Dr). Adverum/Lilly RTP fits between Days 1–2 (verify ownership autonomy first).
Priority: Cellectis → Lindy → ChromaGenix → Synoligo/Asymchem → Sterling.
Day 3 — Universities & incubators (lead generation)
NC State (Raleigh): BTEC (book the tour) + AIM-Bio. Chapel Hill: UNC Gene Therapy Center / Vector Core, BioLabs Chapel Hill, Innovate Carolina. Durham: Duke Asokan/Gersbach labs, Duke R&D @RTP, NCCU BRITE, and BioLabs Durham + FFVC for tenant density. This day seeds the next 12 months of pipeline.
Day 4 (optional) — Outer ring + verification
Clayton (Johnston Co): Grifols (clamp-on/expansion angle) + Johnston CC. Quietly verify CARsgen Durham status. Touch the multinational new-builds' integrator/EPC angle (AbbVie Durham, Genentech Holly Springs) by phone.
Sequencing tips:
- Lead the whole trip around the active build-outs (OXB, AMP, Kriya, Kincell, Alcami, ChromaGenix) — that's where the spec/procurement window is open now.
- Bookend days with networking events — WIB Career Fair (Jun 25), TBT (mid-July), NCLifeSci Luncheon (Jul 23) are the highest-yield rooms; time the visit to catch at least one.
- Use NCBiotech, Hatteras, Cape Fear BioCapital, RTP.org as your intro engine to convert the watch-list into qualified calls.
- Don't burn windshield time on the skip/low list — but keep Solvias and FlashPath's Sara Selitsky as referral nodes into wet-lab accounts that do fit.